Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test

被引:73
|
作者
Warnecke, Tobias [1 ]
Suttrup, Inga [1 ]
Schroeder, Jens B. [1 ]
Osada, Nani [2 ]
Oelenberg, Stephan [1 ]
Hamacher, Christina [1 ]
Suntrup, Sonja [1 ]
Dziewas, Rainer [1 ]
机构
[1] Univ Hosp Munster, Dept Neurol, Albert Schweitzer Campus 1, D-48149 Munster, Germany
[2] Univ Munster, Dept Med Informat, Domagkstr 9, D-48149 Munster, Germany
关键词
Parkinson's disease; Dysphagia; Swallowing; FEES; Levodopa responsiveness; DOPAMINERGIC STIMULATION; SWALLOWING ABNORMALITIES; AGREEMENT; DIAGNOSIS; THERAPY;
D O I
10.1016/j.parkreldis.2016.04.034
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: It is still controversially discussed whether central dopaminergic stimulation improves swallowing ability in Parkinson's disease (PD). We evaluated the effect of oral levodopa application on dysphagia in advanced PD patients with motor fluctuations. Methods: In 15 PD patients (mean age 71.93 +/- 8.29 years, mean disease duration 14.33 +/- 5.94 years) with oropharyngeal dysphagia and motor fluctuations endoscopic swallowing evaluation was performed in the off state and on state condition following a specifically developed protocol (FEES-levodopa-test). The respective dysphagia score covered three salient parameters, i.e. premature spillage, penetration/aspiration events and residues, each tested with liquid as well as semisolid and solid food consistencies. An improvement of >30% in this score indicated levodopa responsiveness of dysphagia. Measures were compared between the off-and on-state condition by using the Wilcoxon Test and marginal homogeneity test. Inter- and intrarater reliability was also investigated. Results: Severity of swallowing dysfunction in the off state varied widely. The lowest dysphagia score was 15 points (dysphagia without any aspiration risk). The highest dysphagia score was 84 points (dysphagia with aspiration of all consistencies). Seven patients showed a marked improvement of dysphagia in the on state condition. Eight PD patients did not respond. Inter- and intrarater reliability was excellent for all three subscales in the off state and on state conditions. Conclusions: A significant proportion of advanced PD patients with motor fluctuations and mild to moderate oropharyngeal dysphagia may demonstrate a clinically relevant improvement of swallowing after levodopa challenge. The FEES-levodopa-test is a reliable and sensitive tool to differentiate these responders from non-responders. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:100 / 106
页数:7
相关论文
共 50 条
  • [21] Complications of levodopa therapy in Parkinson's disease
    Dubow, Jordan
    Olanow, C. Warren
    EXPERT OPINION ON ORPHAN DRUGS, 2019, 7 (09): : 391 - 397
  • [22] Unmasking levodopa resistance in Parkinson's disease
    Nonnekes, Jorik
    Timmer, Monique H. M.
    de Vries, Nienke M.
    Rascol, Olivier
    Helmich, Rick C.
    Bloem, Bastiaan R.
    MOVEMENT DISORDERS, 2016, 31 (11) : 1602 - 1609
  • [23] Levodopa in the early treatment of Parkinson's disease
    Murata, Miho
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S17 - S20
  • [24] Is levodopa the best treatment for Parkinson's disease?
    Tolosa, E
    EUROPEAN JOURNAL OF NEUROLOGY, 1996, 3 : 5 - 7
  • [25] Levodopa Response in Early Parkinson's Disease
    Hauser, Robert A.
    Auinger, Peggy
    Oakes, David
    MOVEMENT DISORDERS, 2009, 24 (16) : 2328 - 2336
  • [26] Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease
    Zappia, M
    Montesanti, R
    Colao, R
    Branca, D
    Nicoletti, G
    Aguglia, U
    Quattrone, A
    MOVEMENT DISORDERS, 1997, 12 (01) : 103 - 106
  • [27] Levodopa and cognitive disorders in Parkinson's disease
    Leiva-Santana, C.
    Alvarez-Sauco, M.
    REVISTA DE NEUROLOGIA, 2006, 43 (02) : 95 - 100
  • [28] Optimisation of treatment of Parkinson's disease with levodopa
    Bialecka, Monika
    Adamiak, Urszulo
    Gawronska-Szklarz, Barbara
    NEUROLOGIA I NEUROCHIRURGIA POLSKA, 2009, 43 (05) : 446 - 459
  • [29] Levodopa--carbidopa intestinal gel for treatment of advanced Parkinson''s disease
    Fernandez, H. H.
    Odin, P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 907 - 919
  • [30] Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease
    Westin, J.
    Nyholm, D.
    Groth, T.
    Dougherty, M. S.
    Yerramsetty, P. K.
    Palhagen, S. E.
    PARKINSONISM & RELATED DISORDERS, 2006, 12 (08) : 509 - 513